Recap: Artelo Biosciences Q4 Earnings
Portfolio Pulse from Benzinga Insights
Artelo Biosciences (NASDAQ:ARTL) reported Q4 earnings with an EPS of $-0.99, missing estimates by -77.0% and showing no revenue change from the previous year. Despite past earnings misses, the company's share price increased by 3.0% the day after the last earnings report.
March 25, 2024 | 1:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Artelo Biosciences reported a significant miss in Q4 earnings with an EPS of $-0.99, underperforming estimates by -77%, and no change in revenue from the previous year.
The significant miss in earnings estimates and the lack of revenue growth are likely to negatively impact investor sentiment towards ARTL in the short term. Historically, earnings misses can lead to a decrease in stock price, although ARTL saw a 3% increase after the last miss, indicating potential volatility.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100